If you would like more information or are interested in our clinical trials please contact Marilyn, our trial director at (203) 365-6565.
Trial Director: Rebecca B.
Contact: (203)787-6161
Alcon Research – 2015 to PRESENT – RTH Solution for Intravitreal Injection
Neovascular AMD
Rth258-C001
Chiltren - (2016 to 2017) – Squalamine Lactate Ophthalmic Solution
Neovasular AMD
OHR-1601
Opthotech – 2013 to 2016 - Fovista
Choroidal neovascularization secondary to AMD
OPH1002-AMD
Xoma Eye Guard – 2013 to 2015 – Gevokizumab
Active Non-infectious Intermediate, Posterior, or Pan- Uveitis
XO52130/CL3-78989-005
XO52131/CL3-78989-006
X052132 – Rollover
Lux Biosciences 2011-2011 - Luminate
Treatment of Intermediate and Posterior Non-Infectious Uveitis
Alcon Pharmaceuticals 2010-2011 – Durezol vs Pred Forte
Treatment for Anterior Uveitis
1034 Phase III
Regeneron Pharmaceuticals 2008 – 2013 – Eylea
Neovascular AMD
VGTF-OD-0605 / View
VGTF-OD 0910
Allergan Pharmaceuticals 2006 – 2014 - Dexanmethasone
DME 206207-011
DME 206207-012
RVO 203207-009
Brimonidine GA 190342-032D
Genentech Pharmaceuticals 2004- 2013 – Lucentis
FVF4168g Ride Phase III - DME
FVF3192g Pier - AMD
FVF3689g Sailor – AMD
Eyetech Pharmaceuticals 2002- 2008 - Macugen
EOP 1003- AMD
EOP1006 - AMD
EOP1010 - AMD
EOP 1023 - DME
